Latest Breaking News On - Boehringer ingelheim animal health in duluth - Page 4 : comparemela.com

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Anna bergmannMohamed eidJennifer forsythEli lillyJeff emmickYork heart associationGlobal business communicationsBoehringer ingelheim pharmaceuticals incClinical development medical affairsDrug administrationBoehringer ingelheimBoehringer ingelheim animal health in duluthExchange commissionBoehringer ingelheim corporationProduct developmentAnimal health

Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction

Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Stefan ankerGreg kuetermanMohamed eidJennifer forsythEli lillyJeff emmickBoehringer ingelheim pharmaceuticals incClinical development medical affairsEuropean commissionBoehringer ingelheimDrug administrationBoehringer ingelheim animal health in duluthExchange commissionBoehringer ingelheim corporationProduct developmentEuropean society of cardiology

VOLTAIRE-X phase III data in patients with moderate-to-severe chronic plaque psoriasis support interchangeability application

Share this article Share this article RIDGEFIELD, Conn., April 23, 2021 /PRNewswire/ Boehringer Ingelheim today announced results from a phase III, randomized study that concluded that switching several times from Humira® (adalimumab) to Cyltezo® (adalimumab-adbm) produced similar clinical outcomes in terms of pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate-to-severe chronic plaque psoriasis. The 32-week data will be presented at the American Academy of Dermatology 2021 virtual meeting experience. We are proud to present the results from Voltaire-X, a landmark study that supports Boehringer Ingelheim s application for interchangeability between Cyltezo® and Humira®, said Thomas Seck, Senior Vice President, Medicine and Regulatory Affairs at Boehringer Ingelheim. This first-of-its-kind switching study further reinforces our goal to broaden access to biosimilar treatment options while contributing to the quality and sustainability of healt

United statesThomas seckBoehringer ingelheim biopharmaRegulatory affairs at boehringer ingelheimAbbvie biotechnology ltdBoehringer ingelheim pharmaceuticals incBoehringer ingelheimDrug administrationBoehringer ingelheim animal health in duluthBoehringer ingelheim corporationAmerican academy of dermatologyAnimal healthBoehringer ingelheim fremont incAmerican academySenior vice presidentRegulatory affairs

Boehringer Ingelheim Animal Health Announces U S Leadership Transition

Share this article DULUTH, Ga., Jan. 13, 2021 /PRNewswire/ Boehringer Ingelheim Animal Health, a leading provider of medicine for pets, horses and livestock, announced today the appointment of Randolph Legg as its U.S. President. He succeeds Everett Hoekstra, who retired in December. Legg will remain head of the Company s U.S. commercial business while serving as president. (PRNewsfoto/Boehringer Ingelheim, Inc.) It s my honor to lead an organization dedicated to enhancing the well-being of people and animals, he said. Legg held various commercial leadership roles in Boehringer Ingelheim s Human Pharmaceutical division before moving to the company s Animal Health business in 2019 to lead the U.S. Pets Commercial team. He is based at the U.S. headquarters of Boehringer Ingelheim Animal Health in Duluth, Ga.

Puerto ricoUnited statesRheinland pfalzNew jerseyJean michel boersBoehringer ingelheim animal healthHuman pharmaceuticalsOperations in global animal healthBoehringer ingelheim united states corpBoehringer ingelheimBoehringer ingelheim animal health in duluthBoehringer ingelheim incAnimal healthHuman pharmaceuticalIngelheim animal healthHelmut finkler

Boehringer Ingelheim announces leadership transition

Jan 13, 2021 Boehringer Ingelheim Animal Health recently announced the appointment of Randolph Legg as its U.S. president. He succeeds Everett Hoekstra, who retired in December. Legg will remain head of the company s U.S. commercial business while serving as president. It s my honor to lead an organization dedicated to enhancing the well-being of people and animals, he said. Legg held various commercial leadership roles in Boehringer Ingelheim s Human Pharmaceutical division before moving to the company s Animal Health business in 2019 to lead the U.S. Pets Commercial team. He is based at the U.S. headquarters of Boehringer Ingelheim Animal Health in Duluth, Ga.

Rheinland pfalzUnited statesJean michel boersEverett hoekstraHelmut finklerRandolph leggBoehringer ingelheim animal healthHuman pharmaceuticalsOperations in global animal healthBoehringer ingelheim united states corpBoehringer ingelheimBoehringer ingelheim animal health in duluthAnimal healthHuman pharmaceuticalIngelheim animal healthRegional bio manufacturing americas